AVEO has 4Qs of higher revenues, but its losses continue to increase.<g>
However, today it bounced up from the support te the $7.50 level and and was up 12.56% at 2:00pm closing up 4.45% on moderate volume about half its ADV
bigcharts.marketwatch.com
AVEO released today some data at ASCO from its PII of tivozanib, showing that the median progression-free survival achieved by patients with advanced clear cell renal cell Ca., who had undergone a prior nephrectomy was 14.8 months.
It said that side effects and toxicities commonly associated with other targeted therapies, such as mucositis, fatigue and hand-foot syndrome, were low during treatment with tivozanib.
Michael B. Atkins, M.D., professor of medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, stated: "The efficacy observed with tivozanib in this PII compares favorably to historical data from trials testing currently approved VEGF receptor inhibitors in patients with advanced kidney Ca., and the tolerability profile underscores the potential for improved quality of life"
Some of these data had already been presented in March at the Genitourinary Cancers Symposium
AVEO has started enrollment in TIVO-1, a PIII of tivozanib, which is expected to enroll approximately 500 patients with advanced RCC who have not received prior VEGF-targeted therapy.
The ACTAY is $14
The stock is just starting to get off from the DT coming from the April 22 H at $9.91
The EL for 2010 is around $2.55 vs. $1.42 last Yr.
I think I will just keep a target at the $9, pending further developments.<g>
bigcharts.marketwatch.com
Bernard |
